Wed Sep 25 07:49:00 UTC 2024: ## Black Diamond Therapeutics (BDTX) Receives Positive Analyst Ratings and Institutional Investment
**New York, NY** – Black Diamond Therapeutics (NASDAQ:BDTX), a clinical-stage oncology company developing targeted therapies for genetically defined tumors, is attracting significant investor interest.
HC Wainwright reiterated their “Buy” rating on BDTX shares, setting a $11.00 target price. Other analysts also expressed optimism, with Piper Sandler increasing their price target from $12.00 to $15.00 and giving the stock an “Overweight” rating. Raymond James initiated coverage with an “Outperform” rating and a $20.00 target price, while Wedbush reaffirmed their “Outperform” rating with a $16.00 price objective.
Black Diamond Therapeutics recently exceeded analysts’ expectations with their quarterly earnings, reporting a ($0.36) EPS compared to the consensus estimate of ($0.39).
Institutional investors are also bullish on BDTX. Susquehanna Fundamental Investments, SG Americas Securities, Jump Financial, Algert Global, and Pale Fire Capital have all made recent investments in the company.
Black Diamond Therapeutics is currently focusing on its lead product candidate, BDTX-1535, a potential treatment for epidermal growth factor receptor mutant non-small cell lung cancer and glioblastoma.
The company’s strong financial performance, positive analyst sentiment, and growing institutional investor interest suggest a bright future for Black Diamond Therapeutics.
First Piper 